Charles D Murray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/830824/publications.pdf

Version: 2024-02-01

100 papers

3,405 citations

28 h-index 56 g-index

106 all docs

 $\begin{array}{c} 106 \\ \\ \text{docs citations} \end{array}$

106 times ranked 4644 citing authors

#	Article	IF	CITATIONS
1	Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis. Rheumatology, 2022, 61, 781-786.	1.9	7
2	Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2022, 74, 208-214.	1.8	9
3	The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder. Journal of Clinical Immunology, 2022, 42, 312-324.	3.8	8
4	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
5	Endoscopy during the peak of COVID-19 pandemic: impact on activity and financial implications for a tertiary referral center in London. Annals of Gastroenterology, 2021, 34, 829-835.	0.6	O
6	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
7	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23
8	Constipation, Bloating and Abdominal Pain. In Clinical Practice, 2021, , 167-178.	0.0	0
9	Editorial: fatigue—difficult to assess and difficult to treat. Alimentary Pharmacology and Therapeutics, 2021, 53, 339-339.	3.7	1
10	Radiological findings in gastrointestinal scleroderma. Journal of Scleroderma and Related Disorders, 2020, 5, 21-32.	1.7	3
11	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
12	P156â€fUnderstanding the associations and impact of severe gastrointestinal involvement in systemic sclerosis: a structured approach. Rheumatology, 2020, 59, .	1.9	0
13	UEG Guidelines framework to guide clinical practice. United European Gastroenterology Journal, 2020, 8, 845-846.	3.8	0
14	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterology, 2020, 11, 343-350.	1.8	37
15	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28
16	The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy. Current Medical Research and Opinion, 2020, 36, 977-983.	1.9	1
17	UEG Education—building on success. United European Gastroenterology Journal, 2020, 8, 119-120.	3.8	6
18	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	12.1	232

#	Article	IF	CITATIONS
19	Chronic Granulomatous Disorder–Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level. Journal of Clinical Immunology, 2019, 39, 494-504.	3.8	6
20	Editorial: combination immunosuppressive therapy to treat Crohn's disease – ready for all age groups?. Alimentary Pharmacology and Therapeutics, 2019, 49, 1528-1528.	3.7	1
21	Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia. United European Gastroenterology Journal, 2019, 7, 217-224.	3.8	9
22	Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis. Arthritis Research and Therapy, 2019, 21, 81.	3.5	7
23	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
24	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	7.4	129
25	Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. Health Technology Assessment, 2019, 23, 1-162.	2.8	10
26	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 714-724.	1.9	102
27	There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scandinavian Journal of Rheumatology, 2018, 47, 62-70.	1.1	28
28	Editorial: antiâ€≺scp>TNF therapy and myopenia in Crohn's diseaseâ€"another step towards personalised medicine. Alimentary Pharmacology and Therapeutics, 2018, 47, 141-142.	3.7	1
29	In memory of Dr Tomer Adar. United European Gastroenterology Journal, 2018, 6, 1437-1437.	3.8	1
30	A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population. Digestive Diseases and Sciences, 2018, 63, 3049-3057.	2.3	13
31	Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease. Human Genetics, 2018, 137, 723-734.	3.8	8
32	Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 548-558.	8.1	143
33	Gallstone mimicry: a rare cause of abdominal pain. Gut, 2017, 66, 1251-1251.	12.1	0
34	UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut, 2017, 66, 988-1000.	12.1	74
35	The Impact of Transition to Adult Gastroenterology Services on Health-Related Quality of Life in Young Adult Patients with IBD: The UK Transit Study. Gastroenterology, 2017, 152, S800-S801.	1.3	0
36	Structured Transition Enhances Clinical Outcome without an Increase in Healthcare Cost in Adolescent Patients with IBD: the UK Transit Study. Gastroenterology, 2017, 152, S369.	1.3	3

#	Article	IF	Citations
37	PTH-041â€Definitive management of a very rare cause of significant acute upper gastrointestinal bleeding: gastric lipoma resected by hybrid endoscopic submucosal dissection., 2017,,.		O
38	Small and Large Intestinal Involvement and Nutritional Issues. , 2017, , 443-458.		1
39	Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. European Journal of Gastroenterology and Hepatology, 2016, 28, 786-791.	1.6	16
40	The role of dietary supplements in inflammatory bowel disease: a systematic review. European Journal of Gastroenterology and Hepatology, 2016, 28, 1357-1364.	1.6	49
41	Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy. Endoscopy, 2016, 48, E403-E404.	1.8	6
42	Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy. Endoscopy, 2016, 48, E14-E15.	1.8	2
43	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 273-282.	8.1	91
44	The ABC of E-learning: Utilizing E-learning resources for training and research in gastroenterology. United European Gastroenterology Journal, 2016, 4, 623-624.	3.8	2
45	I33â€∱Management of Gastrointestinal Vascular Manifestations of Systemic Sclerosis. Rheumatology, 2016, , .	1.9	0
46	Gastrointestinal manifestations of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 247-256.	1.7	106
47	P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS. Digestive and Liver Disease, 2016, 48, e195.	0.9	0
48	Travel health and pretravel preparation in the patient with inflammatory bowel disease. Frontline Gastroenterology, 2016, 7, 60-65.	1.8	17
49	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	1.3	85
50	Relapse after withdrawal from antiâ€ <scp>TNF</scp> therapy for inflammatory bowel disease: an observational study, plus systematic review and metaâ€analysis. Alimentary Pharmacology and Therapeutics, 2016, 43, 910-923.	3.7	87
51	Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology, 2016, 55, 115-119.	1.9	62
52	Gut symptoms in diabetics correlate with components of the rectoanal inhibitory reflex, but not with pudendal nerve motor latencies or systemic autonomic neuropathy. Journal of Digestive Diseases, 2015, 16, 342-349.	1.5	8
53	CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 13-18.	2.9	43
54	Sa1264 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centred Pilot Study to Assess the Symptomatic Treatment of Ulcerative Colitis With Cannabidiol. Gastroenterology, 2015, 148, S-275.	1.3	2

#	Article	IF	Citations
55	Intractable diarrhoea despite immune reconstitution in an HIV positive man. Journal of Clinical Virology, 2015, 69, 219-222.	3.1	1
56	A rare cause of abdominal pain, diarrhoea and GI bleeding. Gut, 2015, 64, 214-214.	12.1	17
57	Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease. BMJ Case Reports, 2015, 2015, bcr2014206854-bcr2014206854.	0.5	6
58	PTH-056ÂTrial to assess cannabidiol in the symptomatic treatment of ulcerative colitis. Gut, 2015, 64, A430.1-A430.	12.1	2
59	Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. ELife, 2015, 4, e09115.	6.0	34
60	Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms. , 2015, , .		0
61	Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S168-70.	0.8	10
62	UEG Education: time to shape the future. United European Gastroenterology Journal, 2014, 2, 445-445.	3.8	1
63	P553 A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, S298.	1.3	0
64	P574 A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel. Journal of Crohn's and Colitis, 2014, 8, S307-S308.	1.3	1
65	METRIC (MREnterography or ulTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. BMC Gastroenterology, 2014, 14, 142.	2.0	36
66	OC-055â€lbd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation. Gut, 2014, 63, A27.1-A27.	12.1	1
67	PTU-092â€Patient And Professionals Perceptions Of Travel Behaviour In Inflammatory Bowel Disease. Gut, 2014, 63, A79.2-A80.	12.1	0
68	PWE-115â€Patients Continue To Travel Abroad Despite Recently Active Disease And Travel Concerns: Results Of A Single Centre Study In Inflammatory Bowel Disease And Travel. Gut, 2014, 63, A175.1-A175.	12.1	1
69	PWE-183â€Preliminary Significant Findings From A Randomised Control Trial Of Posterior Tibial Nerve Stimulation In Systemic Sclerosis Associated Faecal Incontinence. Gut, 2014, 63, A206.1-A206.	12.1	2
70	Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World Journal of Gastroenterology, 2014, 20, 17352.	3.3	50
71	Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clinical and Experimental Rheumatology, 2014, 32, S-214-21.	0.8	21
72	Bloody Diarrhoea. Lancet, The, 2013, 382, e3.	13.7	0

#	Article	IF	Citations
73	Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF1± therapy. Journal of Crohn's and Colitis, 2013, 7, 412-418.	1.3	20
74	Weight loss and lumbosacral back pain in a 79-year-old Indian man. Gut, 2013, 62, 1504-1504.	12.1	0
75	Using an †action set†for the management of acute upper gastrointestinal bleeding. Therapeutic Advances in Gastroenterology, 2013, 6, 426-437.	3.2	5
76	Malignant mimicry—a 17-year-old with abdominal pain and weight loss. Gut, 2013, 62, 995-995.	12.1	0
77	PTH-132 Iron Deficiency Anaemia Nurse Led Clinic: Audit of 1st Year. Gut, 2013, 62, A265.1-A265.	12.1	0
78	Current renewable energy generator technical interconnection requirements. , 2012, , .		1
79	P57â€Comparative Cost-Effectiveness of IGRA to Detect Latent TB Infection in UK Inflammatory Bowel Disease Patients Initiating Anti-TNFα Agents: Abstract P57 Table 1. Thorax, 2012, 67, A87.3-A88.	5.6	0
80	PTU-113â€Quality of life in patients with ileoanal pouch: a survey comparing two different patient populations. Gut, 2012, 61, A231.2-A232.	12.1	0
81	PTU-096â€The use of commercial interferon-γ release assays to screen for mycobacterial infection in inflammatory bowel disease patients initiating anti-TNF agents. Gut, 2012, 61, A223.1-A223.	12.1	0
82	Do We Do Enough to Convince Our Patients With Crohn's Disease to Stop Smoking? Results From a North London Audit. Gastroenterology, 2011, 140, S-784.	1.3	0
83	There will be blood a complete audit cycle. Gut, 2011, 60, A188-A189.	12.1	0
84	Iron deficiency anaemia is common in patients with an ileoanal pouch and is not always associated with inflammation. Gut, 2011, 60, A205-A205.	12.1	1
85	Influence of smoking and other environmental factors in inflammatory bowel disease activity: what do our patients think?. Gut, 2011, 60, A210-A210.	12.1	0
86	Attitudes and Experiences of Adolescents in an Innovative IBD Transition Service. Gastrointestinal Nursing, 2011, 9, 35-40.	0.1	7
87	Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2009, 29, 552-560.	3.7	43
88	The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion. Appetite, 2008, 51, 747-750.	3.7	39
89	Reaping value from intellectual property: DuPont's strategic approach achieves global growth. Strategy and Leadership, 2007, 35, 36-42.	0.5	8
90	Pharmacological modulation of gut mucosal and large vessel blood flow. Alimentary Pharmacology and Therapeutics, 2007, 25, 693-702.	3.7	6

#	Article	IF	Citations
91	Diabetes and the Gastrointestinal System. , 2006, , 169-202.		0
92	Ghrelin augments afferent response to distension in rat isolated jejunum. Neurogastroenterology and Motility, 2006, 18, 1112-1120.	3.0	12
93	The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients. Clinical Nutrition, 2006, 25, 626-633.	5.0	34
94	Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon. European Journal of Pharmacology, 2005, 524, 138-144.	3 . 5	58
95	Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut, 2005, 54, 1693-1698.	12.1	284
96	Sporadic duodenal adenoma is associated with colorectal neoplasia. Gut, 2004, 53, 261-265.	12.1	86
97	Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome. Gastroenterology, 2004, 127, 1695-1703.	1.3	151
98	Ghrelin for the gastroenterologist: history and potential. Gastroenterology, 2003, 125, 1492-1502.	1.3	89
99	Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation. Gastroenterology, 2003, 124, A570.	1.3	0
100	Medical management of diverticular disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 611-620.	2.4	4